Hero image with Pittsburgh background https://pittplusme.org/study/jakpotadult

STUDY BASICS

Were you recently diagnosed with type 1 diabetes? Are you 18-35 years old? You may be eligible for a research study to see if two inhibitors can preserve insulin production in people recently diagnosed with type 1 diabetes (T1D). Compensation is provided.


STUDY PURPOSE

TrialNet is testing two different Janus kinase (JAK) inhibitors to see if either or both can preserve insulin production in people recently diagnosed with type 1 diabetes (T1D). 


COULD THIS STUDY BE RIGHT FOR YOU?

Eligible participants:

  • Are ages 18-35
  • Are newly diagnosed with T1D (in past 3 months)

WHAT PARTICIPANTS CAN EXPECT

The two JAK inhibitors being tested in this study are abrocitinib and ritlecitinib. To understand which treatment works best, participants will be randomly assigned to one of three groups: one group will get abrocitinib, one will get ritlecitinib, and one will get a matching placebo (looks like the study treatment but has no active ingredients). 

Participants will be followed for two years. The first year will be the treatment phase and will involve scheduled monitoring visits, and some visits include mixed meal tolerance tests (MMTT). The second year will involve two visits—at 18 and 24 months—where mixed meal tolerance tests (MMTT) will also be performed.  


IRB: STUDY23050160B
- JAK Inhibitors to Preserve C-Peptide Production in New Onset T1D

RESEARCH AREAS & CONDITIONS:
  Featured Research, Precision Medicine


PHONE NUMBER: 1-866-438-8230
SHARE STUDY
Printer Printer   Email A FriendEmail A Friend   ShareShare   TweetTweet   Linked-InLinked-In

INTERESTED?

Visit https://pittplusme.org/study/jakpotadult and click on "I'm Interested" or call 1-866-438-8230.


LEARN MORE

PittPlusMe.org
1-866-438-8230
PittPlusMe@pitt.edu
@PittPlusMe
@PittPlusMe

MEET THE RESEARCHER


Ingrid Libman DeGordon

Ingrid Libman DeGordon, MD, PhD, is an Associate Professor in the Division of Pediatric Endocrinology at the University of Pittsburgh School of Medicine and Director of the UPMC Children’s Hospital of Pittsburgh Diabetes Program. A graduate of the University of Pittsburgh Graduate School of Public Health, Dr. Libman’s research interests include prediction, prevention and management of diabetes in youth, the impact of obesity in type 1 diabetes and the concept of “double” diabetes in childhood.